Mesa Laboratories/$MLAB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Mesa Laboratories
Mesa Laboratories Inc manufactures life sciences tools and critical quality control solutions. It operates in four divisions: i) Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. ii) Clinical Genomics division develops, manufactures, and sells sensitive, low-cost, high-throughput genetic analysis tools and related consumables. iii) The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. iv) The Calibration Solutions division develops, manufactures, sells, and services quality control products.
- Ticker
- $MLAB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 717
- Headquarters
- Lakewood, United States
- Website
- www.mesalabs.com
MLAB Metrics
BasicAdvanced
$715M
148.47
$0.86
0.96
$0.64
0.50%
Price and volume
Market cap
$715M
Beta
0.96
52-week high
$144.35
52-week low
$69.51
Average daily volume
101K
Dividend rate
$0.64
Financial strength
Current ratio
1.794
Quick ratio
1.163
Long term debt to equity
0.811
Total debt to equity
0.855
Dividend payout ratio (TTM)
73.63%
Interest coverage (TTM)
2.07%
Profitability
EBITDA (TTM)
45.437
Gross margin (TTM)
64.21%
Net profit margin (TTM)
1.92%
Operating margin (TTM)
9.00%
Effective tax rate (TTM)
48.69%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
3.29%
Return on equity (TTM)
2.66%
Valuation
Price to earnings (TTM)
148.47
Price to revenue (TTM)
2.847
Price to book
3.79
Price to tangible book (TTM)
3.79
Price to free cash flow (TTM)
13.445
Free cash flow yield (TTM)
7.44%
Free cash flow per share (TTM)
9.506
Dividend yield (TTM)
0.50%
Forward dividend yield
0.50%
Growth
Revenue change (TTM)
3.04%
Earnings per share change (TTM)
-855.05%
3-year revenue growth (CAGR)
4.43%
10-year revenue growth (CAGR)
11.04%
3-year earnings per share growth (CAGR)
37.13%
10-year earnings per share growth (CAGR)
-10.93%
What the Analysts think about MLAB
Analyst ratings (Buy, Hold, Sell) for Mesa Laboratories stock.
Analyst projections of the future price of Mesa Laboratories stock.
Bulls say / Bears say
Adjusted operating income excluding unusual items rose 19.5% in Q1 FY27, with its margin improving to 25.6% from 21.7%. This suggests cost and operating-efficiency gains are supporting profits despite modest sales growth. (Mesa Laboratories)
Mesa generated $14.7 million of operating cash flow in Q1 FY27, repaid $8.7 million of debt and brought net leverage down to 1.85 times. Continued debt reduction would give it more room to fund investment and manage its balance sheet. (Mesa Laboratories)
Calibration Solutions revenue grew 7.6% and Biopharmaceutical Development revenue grew 5.0% in Q1 FY27. Growth in these divisions offers some offset to weaker areas of the portfolio. (Mesa Laboratories)
Sterilization and Disinfection Control, Mesa’s largest division, saw Q1 revenue fall 3.6% as delivery problems delayed customer shipments. Management has warned that repeated missed delivery dates could lead customers to consider alternatives. (Mesa Laboratories, The Motley Fool)
Mesa expects Clinical Genomics revenue to fall as it exits lower-margin business and focuses on accounts with greater scale. The division also continues to face weakness in China, limiting its near-term growth prospects. (Mesa Laboratories, Mesa Laboratories)
Biopharmaceutical Development has been volatile: organic revenue fell 29.9% in Q4 FY26 amid commercial execution problems and export-control shipment delays, before rising 5.0% in Q1 FY27. That rebound followed delayed orders, so sustained growth is not yet established. (Mesa Laboratories, Mesa Laboratories)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
MLAB Financial Performance
Revenues and expenses
MLAB Earnings Performance
Company profitability
Upcoming events
MLAB News
AllArticlesVideos
Funds containing MLAB
Fund name | Fund size | $MLAB weighting |
|---|---|---|
iShares Automation & Robotics£RBTX | $4.9B | 0.04% |
iShares Automation & Robotics€2B76 | $5.3B | 0.04% |
iShares Automation & Robotics$RBOT | $4.9B | 0.04% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.